Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.42 |
| ▸ | ULK1 | O75385 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837840 | 0.78 | LOXL2 (0.46) | LOXL2ULK1SMN1; SMN2SCN9ASCN10A | |
| SCHEMBL294393 | 0.77 | LOXL2 (0.66) | LOXL2ULK1SMN1; SMN2 | |
| SCHEMBL5444974 | 0.76 | P2RX7 (0.55) | MMP13 | |
| SCHEMBL6521518 | 0.75 | MMP13 (0.42) | MMP13SMN1; SMN2 | |
| SCHEMBL24956517 | 0.74 | LOXL2 (0.48) | LOXL2ULK1CNR2SCN9ASCN10A | |
| SCHEMBL24958708 | 0.74 | LOXL2 (0.48) | LOXL2ULK1CNR2SMN1; SMN2SCN9A | |
| SCHEMBL2670750 | 0.73 | BAZ2B (0.44) | MMP13SCN9ASCN10A | |
| SCHEMBL23684216 | 0.73 | PRMT5 (0.40) | MMP13CNR2 | |
| SCHEMBL23684732 | 0.73 | PRMT5 (0.40) | MMP13CNR2 | |
| SCHEMBL23684214 | 0.73 | PRMT5 (0.40) | MMP13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2225227-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| EP-2062889-A1 | Compounds | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | LOXL2 3946/4885MMP13 3423/4885ULK1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.